研究单位:[1]Biotyx Medical (Shenzhen) Co., Ltd.[2]Beijing Anzhen Hospital, Capital Medical University,Beijing, China[3]Beijing Hospital,Beijing, China[4]Beijing Tsinghua Changgung Hospital,Beijing, China[5]Peking Union Medical College Hospital,Beijing, China[6]Peking University First Hospital,Beijing, China[7]Peking University People's Hospital,Beijing, China[8]Peking University Third Hospital,Beijing, China[9]People's Liberation Army General Hospital,Beijing, China[10]Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing, China[11]Xuanwu Hospital, Capital Medical University,Beijing, China[12]The First People's Hospital of Changzhou,Changzhou, China[13]The First Affiliated Hospital of Chongqing Medical University,Chongqing, China[14]The First Affiliated Hospital of Dalian Medical University,Dalian, China[15]The First Affiliated Hospital of Fujian Medical University,Fuzhou, China[16]The First Affiliated Hospital of Guangxi Medical University,Guangxi, China[17]The First Affiliated Hospital, Zhejiang University School of Medicine,Hangzhou, China[18]The Second Affiliated Hospital of Nanchang University,Nanchang, China[19]Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School,Nanjing, China[20]The First Affiliated Hospital with Nanjing Medical University,Nanjing, China[21]Renji Hospital, Shanghai Jiaotong University School of Medicine,Shanghai, China[22]Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine,Shanghai, China[23]Zhongshan Hospital, Fudan University,Shanghai, China[24]Shengjing Hospital of China Medical University,Shenyang, China[25]The Second Hospital of Hebei Medical University,Shijiazhuang, China[26]Second Hospital of Shanxi Medical University,Taiyuan, China[27]General Hospital of Tianjin Medical University,Tianjin, China[28]Tianjin 4th Centre Hospital,Tianjin, China[29]Henan Provincial People's Hospital,Zhengzhou, China[30]The First Affiliated Hospital of Zhengzhou University,Zhengzhou, China
研究目的:
A prospective, multi-center, randomized trial to assess the safety and effectiveness of Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™) in treating patients with infrapopliteal arterial stenosis or occlusive disease.